ReviewAIMS neuroscience2025
Oxidative genomic or genotoxic stress in neurodegeneration: Mechanisms and therapeutic avenues.
Review in AIMS neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Dietary Polyphenols in Brain Aging: Molecular Mechanisms and Implications for Neurodegeneration.Nutrients · 2026Review
- Humanized Klotho haplotypes cause widespread transcriptomic changes in mouse brain.bioRxiv : the preprint server for biology · 2026Article
- Late-Onset Depression in an Aging World: A Multidimensional Perspective on Risks, Mechanisms, and Treatment.Geriatrics (Basel, Switzerland) · 2026Review
- Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities.Exploration of targeted anti-tumor therapy · 2026Review
- Ultraviolet radiation and neurodegeneration: molecular mechanisms underlying dual neuroprotective and neurotoxic effects.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurons are especially vulnerable because of their high metabolic activity and limited ability to repair damaged DNA. Oxidative genotoxic stress (OGS), which arises from the buildup of short-lived, highly reactive molecules called reactive oxygen species (ROS), can damage neuronal DNA and compromise antioxidant defense mechanisms in neurons. OGS induces considerable forms of DNA damage, including genomic instability, DNA strand breaks (single or double), DNA base modifications such as 8-oxoguanine, and epigenetic changes, leading to compromised neuronal functions. Moreover, OGS is a silent player in mitochondrial DNA damage and mitochondrial dysfunction. Therefore, ROS-mediated OGS is pivotal for initiating and advancing several neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinsonism (PD), and Huntington's disease (HD). However, there is a significant gap in deciphering the molecular pathways involved in OGS-mediated development of neurodegenerative diseases. Hence, this study focused on the molecular mechanisms by which OGS causes neurodegeneration, with a focus on the contributions of neuroinflammation, mitochondrial dysfunction, and defective DNA repair pathways. Additionally, new therapeutic approaches, such as mitochondrial-targeted medications, antioxidant therapies, gene editing tools such as CRISPR/Cas9, and biomarkers for the early diagnosis of these oxidative diseases, have been assessed. A thorough comprehension of these processes opens exciting possibilities for focused treatments in neurodegenerative illnesses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.